Stifel Nicolaus lowered shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a research report sent to investors on Thursday, The Fly reports. Stifel Nicolaus currently has $23.00 price target on the specialty pharmaceutical company’s stock, down from their prior price target of $55.00.

Several other research analysts have also commented on the company. ValuEngine lowered Supernus Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday. TheStreet lowered Supernus Pharmaceuticals from a b- rating to a c+ rating in a research report on Thursday, August 29th. BidaskClub raised Supernus Pharmaceuticals from a hold rating to a buy rating in a research report on Tuesday, November 5th. Cowen set a $50.00 price target on Supernus Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, August 7th. Finally, Mizuho reaffirmed a buy rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the company. Supernus Pharmaceuticals has an average rating of Hold and a consensus price target of $46.50.

Supernus Pharmaceuticals stock traded up $0.57 during midday trading on Thursday, reaching $21.72. 1,010,300 shares of the stock traded hands, compared to its average volume of 579,923. The firm has a market cap of $1.53 billion, a PE ratio of 10.60, a price-to-earnings-growth ratio of 1.02 and a beta of 1.63. Supernus Pharmaceuticals has a 12-month low of $19.35 and a 12-month high of $49.25. The company has a 50-day simple moving average of $26.80 and a two-hundred day simple moving average of $30.29. The company has a current ratio of 2.72, a quick ratio of 2.53 and a debt-to-equity ratio of 0.70.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $0.54 EPS for the quarter, missing the consensus estimate of $0.59 by ($0.05). The firm had revenue of $102.14 million for the quarter, compared to analyst estimates of $108.70 million. Supernus Pharmaceuticals had a return on equity of 21.80% and a net margin of 25.92%. The company’s quarterly revenue was down .8% on a year-over-year basis. During the same period last year, the firm earned $0.52 EPS. Equities research analysts anticipate that Supernus Pharmaceuticals will post 2.14 earnings per share for the current year.

In related news, CEO Jack A. Khattar bought 7,200 shares of the stock in a transaction on Friday, August 23rd. The shares were bought at an average cost of $26.39 per share, for a total transaction of $190,008.00. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 6.57% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Capital Management Corp VA grew its stake in shares of Supernus Pharmaceuticals by 10.7% in the 2nd quarter. Capital Management Corp VA now owns 190,290 shares of the specialty pharmaceutical company’s stock valued at $6,297,000 after purchasing an additional 18,420 shares during the last quarter. Creative Planning boosted its stake in shares of Supernus Pharmaceuticals by 28.3% in the second quarter. Creative Planning now owns 17,228 shares of the specialty pharmaceutical company’s stock valued at $570,000 after buying an additional 3,802 shares in the last quarter. Point72 Hong Kong Ltd boosted its stake in shares of Supernus Pharmaceuticals by 324.1% in the second quarter. Point72 Hong Kong Ltd now owns 1,692 shares of the specialty pharmaceutical company’s stock valued at $56,000 after buying an additional 1,293 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at approximately $548,000. Finally, Provident Investment Management Inc. boosted its stake in shares of Supernus Pharmaceuticals by 13.8% in the second quarter. Provident Investment Management Inc. now owns 726,333 shares of the specialty pharmaceutical company’s stock valued at $24,034,000 after buying an additional 88,099 shares in the last quarter. Institutional investors own 99.14% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Featured Story: Systematic Risk

The Fly

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.